MX2021011137A - Formulaciones estabilizadas que contienen anticuerpos anti-il-33. - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-il-33.Info
- Publication number
- MX2021011137A MX2021011137A MX2021011137A MX2021011137A MX2021011137A MX 2021011137 A MX2021011137 A MX 2021011137A MX 2021011137 A MX2021011137 A MX 2021011137A MX 2021011137 A MX2021011137 A MX 2021011137A MX 2021011137 A MX2021011137 A MX 2021011137A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- antibodies
- formulations containing
- containing anti
- stabilized formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Environmental & Geological Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821661P | 2019-03-21 | 2019-03-21 | |
| PCT/US2020/023795 WO2020191270A1 (en) | 2019-03-21 | 2020-03-20 | Stabilized formulations containing anti-il-33 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011137A true MX2021011137A (es) | 2021-10-22 |
Family
ID=70228884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011137A MX2021011137A (es) | 2019-03-21 | 2020-03-20 | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11596690B2 (https=) |
| EP (1) | EP3941522A1 (https=) |
| JP (2) | JP7695887B2 (https=) |
| KR (1) | KR20210141592A (https=) |
| CN (3) | CN119700966A (https=) |
| AU (1) | AU2020241882A1 (https=) |
| BR (1) | BR112021018727A2 (https=) |
| CA (1) | CA3133995A1 (https=) |
| CL (1) | CL2021002440A1 (https=) |
| CO (1) | CO2021011648A2 (https=) |
| EA (1) | EA202192568A1 (https=) |
| IL (2) | IL286024B2 (https=) |
| MA (1) | MA55362A (https=) |
| MX (1) | MX2021011137A (https=) |
| PH (1) | PH12021552092A1 (https=) |
| SA (1) | SA521430229B1 (https=) |
| SG (1) | SG11202109822XA (https=) |
| TW (2) | TW202519263A (https=) |
| WO (1) | WO2020191270A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| KR20230010239A (ko) * | 2020-05-11 | 2023-01-18 | 메디뮨 리미티드 | 항-il-33 항체의 제형물 |
| CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| CN113842457B (zh) * | 2021-11-04 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 包含抗人白介素-33单克隆抗体的液体制剂 |
| WO2023077685A1 (zh) * | 2021-11-04 | 2023-05-11 | 江苏荃信生物医药股份有限公司 | 包含抗人白介素-33单克隆抗体的浓缩溶液的制备方法及液体制剂 |
| WO2026067832A1 (zh) * | 2024-09-30 | 2026-04-02 | 深圳市小分子新药创新中心有限公司 | 抗il-33单域抗体及其衍生物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| BRPI0108923B8 (pt) * | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GB0600351D0 (en) | 2006-01-10 | 2006-02-15 | Weston Terence E | Safe hypodermic needle |
| IE20080331A1 (en) | 2007-04-26 | 2009-07-08 | Trinity College Dublin | Products for altering cytokine activity and methods therefor |
| AU2008254704A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | IL-33 in inflammatory disease |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| BR112013008366B1 (pt) * | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| EP2768858B1 (en) * | 2011-10-18 | 2018-08-01 | Emory University | Antibodies directed against influenza |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| PL2892927T3 (pl) * | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| KR20180106974A (ko) | 2017-03-16 | 2018-10-01 | 주식회사 엘지화학 | 항-tnf 알파 항체의 액상 제제 |
| WO2020227515A1 (en) * | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN112851814B (zh) * | 2020-03-17 | 2023-07-07 | 西安宇繁生物科技有限责任公司 | 一种靶向bcma的全人源单链抗体及其制备方法与应用 |
| EP4255451A4 (en) * | 2020-12-03 | 2025-01-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
| TW202237639A (zh) * | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
-
2020
- 2020-03-19 TW TW113138408A patent/TW202519263A/zh unknown
- 2020-03-19 TW TW109109133A patent/TWI861073B/zh active
- 2020-03-20 BR BR112021018727A patent/BR112021018727A2/pt unknown
- 2020-03-20 MA MA055362A patent/MA55362A/fr unknown
- 2020-03-20 CN CN202411908169.7A patent/CN119700966A/zh active Pending
- 2020-03-20 EA EA202192568A patent/EA202192568A1/ru unknown
- 2020-03-20 WO PCT/US2020/023795 patent/WO2020191270A1/en not_active Ceased
- 2020-03-20 CA CA3133995A patent/CA3133995A1/en active Pending
- 2020-03-20 CN CN202080021576.XA patent/CN113573733B/zh active Active
- 2020-03-20 AU AU2020241882A patent/AU2020241882A1/en active Pending
- 2020-03-20 EP EP20718107.4A patent/EP3941522A1/en active Pending
- 2020-03-20 IL IL286024A patent/IL286024B2/en unknown
- 2020-03-20 US US16/825,007 patent/US11596690B2/en active Active
- 2020-03-20 MX MX2021011137A patent/MX2021011137A/es unknown
- 2020-03-20 CN CN202411908014.3A patent/CN119700965A/zh active Pending
- 2020-03-20 PH PH1/2021/552092A patent/PH12021552092A1/en unknown
- 2020-03-20 JP JP2021556435A patent/JP7695887B2/ja active Active
- 2020-03-20 KR KR1020217033469A patent/KR20210141592A/ko active Pending
- 2020-03-20 IL IL317899A patent/IL317899A/en unknown
- 2020-03-20 SG SG11202109822X patent/SG11202109822XA/en unknown
-
2021
- 2021-09-02 CO CONC2021/0011648A patent/CO2021011648A2/es unknown
- 2021-09-05 SA SA521430229A patent/SA521430229B1/ar unknown
- 2021-09-20 CL CL2021002440A patent/CL2021002440A1/es unknown
-
2023
- 2023-02-03 US US18/105,772 patent/US20230346929A1/en active Pending
-
2025
- 2025-06-06 JP JP2025094518A patent/JP2025131756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020241882A1 (en) | 2021-10-14 |
| TWI861073B (zh) | 2024-11-11 |
| IL286024B1 (en) | 2025-01-01 |
| IL286024B2 (en) | 2025-05-01 |
| WO2020191270A1 (en) | 2020-09-24 |
| CN113573733B (zh) | 2024-12-31 |
| SG11202109822XA (en) | 2021-10-28 |
| JP7695887B2 (ja) | 2025-06-19 |
| US20200297845A1 (en) | 2020-09-24 |
| TW202519263A (zh) | 2025-05-16 |
| EA202192568A1 (ru) | 2021-12-03 |
| IL317899A (en) | 2025-02-01 |
| US20230346929A1 (en) | 2023-11-02 |
| PH12021552092A1 (en) | 2022-05-30 |
| CN113573733A (zh) | 2021-10-29 |
| EP3941522A1 (en) | 2022-01-26 |
| KR20210141592A (ko) | 2021-11-23 |
| CL2021002440A1 (es) | 2022-04-22 |
| IL286024A (en) | 2021-10-31 |
| US11596690B2 (en) | 2023-03-07 |
| MA55362A (fr) | 2022-01-26 |
| CN119700965A (zh) | 2025-03-28 |
| CO2021011648A2 (es) | 2021-09-30 |
| JP2022526292A (ja) | 2022-05-24 |
| CN119700966A (zh) | 2025-03-28 |
| BR112021018727A2 (pt) | 2022-02-15 |
| SA521430229B1 (ar) | 2024-01-23 |
| CA3133995A1 (en) | 2020-09-24 |
| JP2025131756A (ja) | 2025-09-09 |
| TW202102260A (zh) | 2021-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002440A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| PY1100365A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r). | |
| MX2022014596A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
| UY33515A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| MX2021014332A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3. | |
| CL2023002560A1 (es) | Formulación de anticuerpos estable | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| UY33652A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) | |
| CO2023014918A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3 | |
| CL2024003444A1 (es) | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. | |
| MX2022016218A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4. | |
| CL2022003586A1 (es) | Formulaciones de anticuerpo de activina a y métodos para utilizarlas | |
| CO2026000834A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-bcma x anti-cd3 | |
| MX2024006555A (es) | Formulaciones que comprenden fab-peg. | |
| CY1125584T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| JOP20220097A1 (ar) | كريزانليزوماب يحتوي على صياغات اجسام مضادة |